120
Participants
Start Date
November 1, 2024
Primary Completion Date
November 1, 2027
Study Completion Date
November 1, 2029
Sunvozertinib
300 mg orally once a day, 28 days as one cycle.
Crizotinib
300 mg orally once a day, 28 days as one cycle.
Pralsetinib
400 mg orally once a day, 28 days as one cycle.
Larotrectinib
100 mg orally twice daily, 28 days as one cycle.
Savolitinib
600 mg or 400 mg (weight \<50 kg) orally once a day, 28 days as one cycle.
Pyrotinib
400 mg orally once a day, 28 days as one cycle.
Dabrafenib+Trametinib
Dabrafenib 150 mg orally twice daily, 28 days as one cycle. Trametinib 150 mg orally twice daily, 28 days as one cycle.
Glecirasib
800 mg daily orally, 28 days as one cycle.
Ensartinib
225 mg daily orally, 28 days as one cycle.
RECRUITING
Sun Yat-sen University Cancer Center, Guangzhou
Sun Yat-sen University
OTHER